Journal of Cardiovascular Pharmacology

AUGUST 1, 2024

Thrombosis continues to pose a significant challenge in cardiovascular and cerebrovascular diseases, contributing to severe health complications such as myocardial infarction, acute ischemic stroke, and venous thromboembolism. In this paper, we comment the findings reported by Liu et al.

Cerebrovascular Disease 40

Cerebrovascular Disease Myocardial Infarction Thrombosis Stroke 40

Stroke: Vascular and Interventional Neurology

AUGUST 26, 2024

Stroke: Vascular and Interventional Neurology, Ahead of Print. The objective is to describe a comprehensive analysis of patients with bacterial meningitis exacerbate by cerebrovascular complications. We reviewed the literature on cerebrovascular complications in adult patients with bacterial meningitis.

Cerebrovascular Disease 40

Cerebrovascular Disease Thrombosis Hemorrhage Outcomes 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. The patient was diagnosed with ACA territory stroke complicated by PH2‐type hemorrhagic conversion. She improved clinically and was discharged to rehab with a diagnosis of recurrent hemorrhage attributed to anticoagulant use and recent stroke.

Hemorrhage 40

Hemorrhage AFIB Cerebrovascular Disease Thrombosis 40

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Stroke Journal

DECEMBER 9, 2024

Stroke, Volume 56, Issue 1 , Page 190-193, January 1, 2025. The prevalence of transient ischemic attacks, ischemic stroke, and hemorrhagic stroke did not differ between patients with aPL-positive and aPL-negative MMA.CONCLUSIONS:The prevalence of aPL in patients with MMA is comparable to that in non-MMA controls.

Cerebrovascular Disease 40

Cerebrovascular Disease Thrombosis Hemorrhage Stroke 40

Frontiers in Cardiovascular Medicine

JANUARY 8, 2025

ObjectiveThis meta-analysis aims to evaluate the safety and efficacy of indobufen in the treatment of cardiovascular diseases, cerebrovascular diseases, and thromboembolic disorders. The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions.

Cerebrovascular Disease 52

Cerebrovascular Disease Cardiovascular Disease Myocardial Infarction Angina 52

Frontiers in Cardiovascular Medicine

NOVEMBER 25, 2024

Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, cerebrovascular disease (e.g., stroke), peripheral arterial disease, congenital heart anomalies, deep vein thrombosis, and pulmonary embolism.

Cardiovascular Disease 59

Cardiovascular Disease Peripheral Arterial Disease Cerebrovascular Disease Thrombosis 59